secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001193125-24-164015
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest: amezalpat 6-month OS improvement in HCC (21 vs 15 months); files $205M equity facility
--------------------------------------------------------------------------------

- Median OS 21 months for amezalpat arm vs 15 months control, a six-month advantage.
- Hazard ratio of 0.65 for OS, stable from 0.59 at primary analysis 10 months earlier.
- 20/40 amezalpat patients remain in survival follow-up vs 9/30 control.
- Entered new Open Market Sale Agreement to sell up to $205M of common stock.
- Tempest retains all product rights; data supports potential pivotal Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312524164015/0001193125-24-164015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312524164015/d857887d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-164015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer